U.S. FDA Accepts Merck ’s Gefapixant New Drug Application for Review

KENILWORTH, N.J.--(BUSINESS WIRE) March 1, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news